PATENT CLAIM ANALYSIS

Application Number: 15864236
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "001890"]

Abstract:
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.

Claim (Index 28):
A method of imaging one or more cells, organs, or tissues comprising exposing the one or more cells, organs, or tissues to, or administering to a subject, a detectably effective amount of the composition of  claim 25 .

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.44
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14987032', '13057044', '14211683', '14715115', '15639445']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6925392289576412
- 35 USC 102 Novelty (BERT): 0.5373501048824544
- Combined Prediction Score: 0.6770203165501225
- Mean Citation Score: 295.58476
- Max Citation Score: 361.94476
- Similarity Product: 284.7648575712728

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test